A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
NCT07215975 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2026-02-23
Summary
The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East
Conditions
- β-thalassemia
Interventions
- DRUG
-
Luspatercept
According to the product label
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-26
- Primary Completion
- 2030-02-28
- Completion
- 2031-04-17
- FDA Drug
- Yes
Countries
- Oman
- Saudi Arabia
Study Locations
More Related Trials
-
Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
NCT01749540 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
NCT07338344 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia
NCT06164821 ·Status: RECRUITING ·Phase: NA
-
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
NCT04143724 ·Status: RECRUITING ·Phase: PHASE2
-
To Evaluate Long- Term Safety and Efficacy of Luspatercept
NCT06875219 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India
NCT05891249 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
NCT03342404 ·Status: COMPLETED ·Phase: PHASE2
-
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
NCT06073860 ·Status: RECRUITING
-
Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)
NCT02268409 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
NCT05577312 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
NCT06364774 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
NCT00171171 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major
NCT02342145 ·Status: COMPLETED ·Phase: PHASE4
-
Gene Therapy for Transfusion Dependent Beta-thalassemia
NCT02453477 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
NCT05860595 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Safety Study for Beta Thalassemia Subjects on PTG-300
NCT04054921 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia
NCT03271541 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
NCT00564941 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
NCT02151526 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
NCT00005934 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
NCT00873041 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
NCT01571635 ·Status: TERMINATED ·Phase: PHASE2
-
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
NCT00171301 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000595 ·Status: COMPLETED ·Phase: PHASE2
-
Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand
NCT01609595 ·Status: COMPLETED ·Phase: PHASE2